logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharma to expand its Clevegen trial to focus on Colorectal cancer

Faron Pharmaceuticals Ltd's (LON:FARN) chief executive Markku Jalkanen tells Proactive London's Andrew Scott they're to target more patients with late-stage colorectal cancer as part of the ongoing phase I/II study of its Clevegen immunotherapy drug.

One of the patients currently enrolled in the trial has the most common form of colorectal cancer – called MSI-low – and has seen a “significant shrinkage” in lung metastasis.

The cohort expansion stage is planned for later this year once the optimal dose has been identified.

Quick facts: Faron Pharmaceuticals Ltd

Price: 129 GBX

AIM:FARN
Market: AIM
Market Cap: £50.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18

RNS

Second Price Monitoring Extn

1 week, 2 days ago

Price Monitoring Extension

1 week, 2 days ago

Matins Trial Update

1 week, 5 days ago

Notice of EGM

2 weeks, 3 days ago

Holdings in Company

3 weeks, 5 days ago

Interim results

4 weeks ago

2 min read